Relapsed/Refractory Acute Myeloid Leukemia
Oncology·MeSH: Leukemia, Myeloid, Acute
Prevalence
6.0 / 100K
Incidence
4.3 / 100K/yr
3 drugs in development·3 companies·2 clinical trials
Drug Pipeline by Phase
Phase 2(2)
Phase 1(1)
| Drug | Company |
|---|---|
| CLN-049 | Cullinan Therapeutics, Inc. (CGEM) |
Compare drugs
Frequently asked questions
How many drugs are in development for Relapsed/Refractory Acute Myeloid Leukemia?
BioSniper tracks 3 drugs in development for Relapsed/Refractory Acute Myeloid Leukemia across 3 companies.
How many clinical trials target Relapsed/Refractory Acute Myeloid Leukemia?
There are 2 clinical trials targeting Relapsed/Refractory Acute Myeloid Leukemia tracked by BioSniper.
What is the prevalence of Relapsed/Refractory Acute Myeloid Leukemia?
The estimated prevalence of Relapsed/Refractory Acute Myeloid Leukemia is approximately 6.0 per 100,000 population.
Deep-dive into Relapsed/Refractory Acute Myeloid Leukemia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis